Canada markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.0000+0.0300 (+0.76%)
At close: 04:00PM EDT
4.1000 +0.10 (+2.50%)
After hours: 06:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.9700
Open4.0020
Bid3.7900 x 1000
Ask4.1500 x 1000
Day's Range3.8350 - 4.0900
52 Week Range3.0500 - 22.9100
Volume648,571
Avg. Volume836,882
Market Cap642.932M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3990
Earnings DateMay 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.23
  • GlobeNewswire

    atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

    – Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health – Key milestones include first subject dosed in Phase 1 KUR-101, launch of drug discovery engine Invyxis, initiation of Psyber usability study in patients and COMPASS’ end of Phase 2 FDA meeting – Ended the first quarter with $335 million cash, maintaining atai’s position as a well-funded, leading mental health company Video int

  • GlobeNewswire

    CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update

    NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued yesterday under the headline "atai Life Sciences to Announce First-Quarter 2022 Financial Results" by atai Life Sciences N.V. (Nasdaq: ATAI), please note the first and second paragraphs, which contained statements referencing the 2022 IR financial results posting and executives on the video interview, as well as forward-looking statements, have been modified. The corrected release follows: atai Life Sciences N.V. (Nasdaq: ATAI) (“ata

  • GlobeNewswire

    atai Life Sciences to Announce First-Quarter 2022 Financial Results

    NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will announce its first-quarter 2022 financial results by posting them on the IR portion of its website. Please visit the atai investor relations website at https://ir.atai.life to view Q1’22 financial results and press release. A video interview with atai Life Sciences CEO Florian Brand, CSO Srinivas